| Bronchospastic disease, Cerebrovascular Insufficiency, CHF, Hypoglycaemia/Diabetes Mellitus, Hepatic disease, Hyperthyroidism, Thyrotoxicosis, Myasthenia Gravis, Narrow-Angle or Angle Closure Glaucoma (only in combination with a miotic), Ophthalmic use may produce additive systemic effects in patients receiving an oral Beta Blocker, Peripheral Vascular Disease, Renal Disease. Avoid gradual withdrawal over a period of 1 to 2 weeks |